News & Views
Morphosys and Integrated Biotherapeutics Provide Update Regarding Usamriid Biodefense Project
Jul 15 2008
Staphylococcal enterotoxins are involved in a variety of human pathologies ranging from hospital and community-acquired infections, sepsis, toxic shock syndrome, to atopic dermatitis. Staphylococcal enterotoxin B is also considered as a potential agent of bioterrorism. Currently no vaccines or immunotherapeutics are available against staphylococcal toxins or S. aureus infections. The research collaboration between IBT and AbD Serotec follows a novel paradigm in the fight against these pathogens by targeting toxins released by bacteria which can distract the immune system and cause massive and even fatal damage.
"This grant allows us to continue a very promising project initiated by USAMRIID and AbD Serotec", said Dr. M. Javad Aman, President and CSO of IBT,IBT is extremely pleased to have access to AbD`s unique technology for developing antibodies with therapeutic potential in this important medical area.
Today`s news marks yet another promising development of a pre-existing customer relationship of AbD Serotec, comments Dr. Achim Knappik, Head of R&D at AbD Serotec. We look forward to work with Integrated BioTherapeutics on this promising project in the field of infectious diseases which is an interesting research market for AbD Serotec.
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 03 2024 Gandhinagar, India
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA